Akero Therapeutics screened the first patient for a phase 2a clinical trial of AKR-001, an Fc-FGF21 fusion protein under investigation for the treatment of nonalcoholic steatohepatitis, according to a press release.
“We believe AKR-001 has the potential to become a cornerstone therapy for the treatment of NASH by addressing its underlying metabolic drivers and the liver inflammation and fibrosis these drivers cause, and by improving risk factors for cardiovascular disease, which is the leading cause of mortality for these patients,” Andrew Cheng, MD, PhD, president and CEO of Akero

Source link